Prognostic Value of Plasma Galectin-3 Levels in Patients with Coronary Heart Disease and Chronic Heart Failure

International Heart Journal

Volumn 56, Issue 3, 2015, Pages 314-318

  Yu, Xiangdong ^a   Sun, Yuemin ^a   Zhao, Ying ^a   Zhang, Wenjuan ^a   Yang, Zhenwen ^a   Gao, Yuxia ^a   Cai, Heng ^a   Li, Yongle ^a   Wang, Qing ^a   Bian, Bo ^a   Nie, Jing ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Brain natriuretic peptide; Independent predictor; Outcome; Prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

AGED; AREA UNDER THE CURVE; ARTICLE; ATRIAL FIBRILLATION; BLOOD ANALYSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART EJECTION FRACTION; HEART FAILURE; HOSPITAL READMISSION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BLOOD; CHRONIC DISEASE; CORONARY DISEASE; FORECASTING; HEART STROKE VOLUME; MORTALITY; PROGNOSIS;

AGED; AREA UNDER CURVE; BIOLOGICAL MARKERS; CHRONIC DISEASE; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; FORECASTING; GALECTIN 3; HEART FAILURE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PATIENT READMISSION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; STROKE VOLUME;

EID: 84929239409     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.14-304     Document Type: Article

References (23)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-9.
2. Hogenhuis J, Voors AA, Jaarsma T, et al. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail 2007; 9: 787-94.
3. Yanavitski M, Givertz MM. Novel biomarkers in acute heart failure. Curr Heart Fail Rep 2011; 8: 206-11. (Review)
4. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010; 7: 1-8. (Review)
5. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110: 3121-8.
6. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48: 1217-24.
7. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Galectin-3, cardiac structure and function, and longterm mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010; 12: 826-32.
8. Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010; 99: 323-8.
9. Gruson D, Mancini M, Ahn SA, Rousseau MF. Galectin-3 testing: validity of a novel automated assay in heart failure patients with reduced ejection fraction. Clin Chim Acta 2014; 429: 189-93.
10. Tang WH, Shrestha K, Shao Z, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011; 108: 385-90.
11. Felker GM, Fiuzat M, Shaw LK, et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012; 5: 72-8.
12. Gullestad L, Ueland T, Kjekshus J, et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J 2012; 164: 878-83.
13. Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 2013; 15: 511-8.
14. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-59. (Review)
15. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-442. (Review)
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
17. Hrynchyshyn N, Jourdain P, Desnos M, Diebold B, Funck F. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Arch Cardiovasc Dis 2013; 106: 541-6.
18. de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43: 60-8.
19. Tschope C, Kasner M, Westermann D, Gaub R, Poller WC, Schultheiss HP. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 2005; 26: 2277-84.
20. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003; 42: 728-35.
21. Carrasco-Sanchez FJ, Aramburu-Bodas O, Salamanca-Bautista P, et al. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int J Cardiol 2013; 169: 177-82.
22. Motiwala SR, Szymonifka J, Belcher A, et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail 2013; 15: 1157-63.
23. van der Velde AR, Gullestad L, Ueland T, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 2013; 6: 219-26.